Early Tuesday, Teva Pharmaceutical (TEVA) reported adjusted earnings of 56 cents per share on $3.88 billion in second-quarter gross sales. In response, Teva inventory jumped.
X
On common, analysts polled by FactSet anticipated the pharma firm to earn 53 cents per share on $3.71 billion in gross sales.
Within the year-earlier interval, Teva earnings had been 68 cents per share and the corporate reported practically $3.79 billion in gross sales.
For the 12 months, Teva raised the low finish of its gross sales outlook. The corporate now expects $15 billion to $15.4 billion in full-year gross sales. Teva inventory analysts had known as for adjusted earnings of $2.26 per share and $15 billion in gross sales.
In premarket buying and selling on at the moment’s inventory market, Teva inventory superior 6.6% close to 8.80. The transfer put Teva inventory in step with its 200-day shifting common, based on MarketSmith.com.
Extra to comply with.
Comply with Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Merck Outplays The Covid Decline, However Prometheus Buyout Weighs On Income
Pfizer Inventory Wavers As Waning Demand For Covid Merchandise Slashes Gross sales In Half
Choices Buying and selling: How To Begin Utilizing Choices, How To Handle Threat
Comply with Premarket And After-The-Open Motion With IBD Consultants
IBD Inventory Of The Day: See How To Discover, Observe And Purchase The Finest Shares